CNTX

AI Memo

Context Therapeutics

As of 2026-09-09/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

CT-202 first patient dosing • 2026-09-30

Base target: $0 / p=50% prob

Biggest risk

The portfolio is concentrated after CT-95 discontinuation, and the recent ovarian-cancer data reaction highlights binary clinical risk. Delays, weak efficacy, safety issues, or future financing needs could pressure the shares.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Successful CT-202 initiation and constructive CTIM-76 follow-up could re-rate the stock materially from its $0.3763 anchor, while the reported runway allows clinical execution without immediate financing urgency [#PR-EARNINGS-2026-08-05].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-09

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Pipeline concentration increases binary execution risk
Cash runway supports near-term clinical execution
Successful CT-202 initiation and constructive CTIM-76 follow-up could re-rate the stock materially from its $0.3763 anchor, while the reported runway allows clinical execution without immediate financing urgency [#PR-EARNINGS-2026-08-05].

BearKey bullets

Binary efficacy and safety risk across CTIM-76 and CT-202 clinical programs.
Cash runway is management-reported and may be shortened by higher-than-expected clinical or operating costs.
Discontinuation of CT-95 concentrates portfolio and execution risk in two prioritized programs [#PR-EARNINGS-2026-08-05].

WatchKey bullets

CT-202 first patient dosing

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=50%)

Target spread vs base: +97% / -61%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=50%)Bear Target: $0 (p=30%)

Commentary

The stock anchor was $0.3763 on 2026-09-08. Recent coverage highlighted a severe post-ovarian-cancer-data selloff, while analyst revisions, options data, short interest, employee-review data, and social coverage are unavailable [#SERP-1]. Company-reported milestones and runway provide support, but forward visibility remains limited and binary; this is a cautious monitoring view rather than a high-conviction bullish thesis.

As of 2026-09-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Pipeline concentration increases binary execution risk
Cash runway supports near-term clinical execution

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=50% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-09-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.60

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
CT-202 first patient dosing
Management expected the first patient dose in the Phase 1 CT-202 trial during Q3 2026, covering urothelial, colorectal, and triple-negative breast cancers [#PR-EARNINGS-2026-08-05].
Prob 60.00% • Move 25.00% • Priced-in 45.00%
EVENT2027-06-30
CTIM-76 Q3W development update
The company plans to evaluate every-three-week dosing in less heavily pretreated platinum-resistant ovarian-cancer patients in the second half of 2026, with initial Q3W data expected in Q2 2027 [#PR-EARNINGS-2026-08-05].
Prob 55.00% • Move 35.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Pipeline concentration increases binary execution risk
2026-12-31
Context is discontinuing CT-95 and concentrating development on CTIM-76 and CT-202, increasing dependence on a small number of clinical programs [#PR-EARNINGS-2026-08-05].
Prob 80% • Move -20% • Priced-in 65%

Long-term Catalysts

Months to a year

Cash runway supports near-term clinical execution
2027-09-30
Context reported $43.0 million of cash and cash equivalents at June 30, 2026 and expected funding into Q4 2027, reducing immediate financing pressure while the prioritized programs advance [#PR-EARNINGS-2026-08-05].
Prob 75% • Move 10% • Priced-in 70%

Risks

Binary efficacy and safety risk across CTIM-76 and CT-202 clinical programs.
Cash runway is management-reported and may be shortened by higher-than-expected clinical or operating costs.
Discontinuation of CT-95 concentrates portfolio and execution risk in two prioritized programs [#PR-EARNINGS-2026-08-05].
Execution or enrollment delays could defer expected 2026-2027 milestones.
Financing and dilution risk remains possible before meaningful clinical validation.

Peers

Symbol	Summary
ATYR	Same-sector micro-cap biotech context; useful for event-volatility comparison but not a mechanism-matched CTIM-76 peer.
MREO	Same-sector small-cap biotech context; relevant mainly for clinical and financing sensitivity rather than direct pipeline comparability.
SCYX	Same-sector micro-cap biotechnology peer; useful as broad event-driven biotech context, with limited direct comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-09

Loading AI feed…

Symbol

Summary

ATYR

Same-sector micro-cap biotech context; useful for event-volatility comparison but not a mechanism-matched CTIM-76 peer.

MREO

Same-sector small-cap biotech context; relevant mainly for clinical and financing sensitivity rather than direct pipeline comparability.

SCYX

Same-sector micro-cap biotechnology peer; useful as broad event-driven biotech context, with limited direct comparability.